Details for Patent: 9,974,790
Which drugs does patent 9,974,790 protect, and when does it expire?
Patent 9,974,790 protects OPZELURA and is included in one NDA.
Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and fifty-three patent family members in thirty-five countries.
Summary for Patent: 9,974,790
| Title: | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
| Abstract: | The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. |
| Inventor(s): | James D. Rodgers, Stacey Shepard |
| Assignee: | Incyte Corp , Incyte Holdings Corp |
| Application Number: | US15/356,957 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,974,790
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 9,974,790*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,974,790
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1966202 | ⤷ Start Trial | C300574 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | PA2013002 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | CA 2013 00005 | Denmark | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | C20130003 00072 | Estonia | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | 1390005-5 | Sweden | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | 92137 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1966202 | ⤷ Start Trial | PA2013002,C1966202 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
